111 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding.

Abbvie
Integrated Platform for Expedited Synthesis-Purification-Testing of Small Molecule Libraries.

Abbvie
Turning a Substrate Peptide into a Potent Inhibitor for the Histone Methyltransferase SETD8.

Abbvie
Synthesis and Pharmacology of (Pyridin-2-yl)methanol Derivatives as Novel and Selective Transient Receptor Potential Vanilloid 3 Antagonists.

Abbvie
Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2.

Abbvie
Optimization of ADME Properties for Sulfonamides Leading to the Discovery of a T-Type Calcium Channel Blocker, ABT-639.

Abbvie
Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.

Abbvie
Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.

Abbvie
Pyrimidine-based tricyclic molecules as potent and orally efficacious inhibitors of wee1 kinase.

Abbvie
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.

Abbvie
Discovery and development of potent and selective inhibitors of histone methyltransferase g9a.

Abbvie
Synthesis and SAR of 4-aminocyclopentapyrrolidines as orally active N-type calcium channel inhibitors for inflammatory and neuropathic pain.

Abbvie
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.

Abbvie
The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia.

Abbvie
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.

AbbVie
Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712.

Abbvie
Pipeline Impact of Radiolabeled Compounds in Drug Discovery and Development.

Abbvie
Discovery of (R)-(3-fluoropyrrolidin-1-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)quinolin-2-yl)methanone (ABBV-318) and analogs as small molecule Na

Abbvie
Discovery and SAR of 4-aminopyrrolidine-2-carboxylic acid correctors of CFTR for the treatment of cystic fibrosis.

Abbvie
Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 Inhibitors.

Abbvie
Development of Orally Efficacious Allosteric Inhibitors of TNFα via Fragment-Based Drug Design.

Abbvie
Discovery of a Potent and Selective Covalent p300/CBP Inhibitor.

Abbvie
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X

Abbvie
Structure-Based Design of A-1293102, a Potent and Selective BCL-X

Abbvie
Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors.

Abbvie
Design and evaluation of pyrazolopyrimidines as KCNQ channel modulators.

Abbvie
Discovery of

Abbvie
Discovery of ABBV/GLPG-3221, a Potent Corrector of CFTR for the Treatment of Cystic Fibrosis.

Abbvie
Hit-to-lead evaluation of a novel class of sphingosine 1-phosphate lyase inhibitors.

Abbvie
Substituted Indazoles as Nav1.7 Blockers for the Treatment of Pain.

Abbvie
Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection.

Abbvie
Emerging Approaches for the Identification of Protein Targets of Small Molecules - A Practitioners' Perspective.

Abbvie
Targeting lysine specific demethylase 4A (KDM4A) tandem TUDOR domain - A fragment based approach.

Abbvie
Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors.

Abbvie
Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).

Abbvie
De Novo Design, Synthesis, and Biological Evaluation of 3,4-Disubstituted Pyrrolidine Sulfonamides as Potent and Selective Glycine Transporter 1 Competitive Inhibitors.

Abbvie
Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases.

Abbvie
Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors.

Abbvie
Methylpyrrole inhibitors of BET bromodomains.

Abbvie
SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).

Abbvie
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.

Abbvie
Are We There Yet? Applying Thermodynamic and Kinetic Profiling on Embryonic Ectoderm Development (EED) Hit-to-Lead Program.

Abbvie
Substituted quinazolines as HDAC6 inhibitors

Augustine Therapeutics
Covalent inhibitors of coronavirus papain-like protease

UT-Battelle
Disubstituted Pyrimidine Compounds for Ketohexokinase Inhibition

Centennial Therapeutics
FUSED RING DERIVATIVES CONTAINING 1,4-OXAZEPANE

Medshine Discovery
THERAPY BASED ON SYNTHETIC LETHALITY IN SWI/SNF COMPLEX-DYSFUNCTION CANCER

National Cancer Center
COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS

Terns Pharmaceuticals
ANTI-PD-L1 IMMUNOCONJUGATES, AND USES THEREOF

Bolt Biotherapeutics
ORALLY BIOAVAILABLE, BRAIN-PENETRANT COMPOUND WITH SELECTIVITY FOR THE CANNABINOID TYPE 2 RECEPTOR WITH POTENTIAL USE TOWARDS VISCERAL PAIN MANAGEMENT AND NEURODEGENERATIVE DISORDERS

University of Mississippi
TKI permeability enhancers

City of Hope
Spiropyrrolidine derived antiviral agents

Enanta Pharmaceuticals
Methotrexate adjuvants to reduce toxicity and methods for using the same

Tosk
Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Galapagos
Method for preparing pyrrolo[3,2-D]pyrimidine compound, and intermediates thereof

Chia Tai Tianqing Pharmaceutical Group
2-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors

H. Lundbeck
Inhibitors of protease-activated receptor-2

Heptares Therapeutics
Macrocyclic indole derivatives useful as hepatitis C virus inhibitors

Janssen Ireland
Compounds inhibiting leucine-rich repeat kinase enzyme activity

Merck Sharp & Dohme
Heterocyclic modulators of cannabinoid receptors

The Cleveland Clinic Foundation
Slowly on, Slowly off: Bisubstrate-Analogue Conjugates of 5-Iodotubercidin and Histone H3 Peptide Targeting Protein Kinase Haspin.

University of Tartu
1,3-dioxanomorphides and 1,3-dioxanocodides

Rhodes Technologies
Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities

Almirall
2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof

Georgetown University
Bromodomain inhibitors

Abbvie
Therapeutic compounds

Regents of The University of Minnesota
Sulfonamide compounds

Kancera
Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors

Nerviano Medical Sciences
Morpholine compounds and uses thereof

Hoffmann-La Roche
Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors

Novartis
Benzobisthiazoles Represent a Novel Scaffold for Kinase Inhibitors of CLK Family Members.

University College London
Compounds for inhibiting the interaction of BCL2 with binding partners

Novartis
Benzamides

H. Lundbeck
Synthesis, antioxidant and anticholinesterase activities of novel coumarylthiazole derivatives.

Bezmialem Vakif University
Anticancer compounds

Boehringer Ingelheim International
Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase

Fibrogen
Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds

Array Biopharma
Organic compounds

Novartis
Imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines as mark inhibitors

Merck Sharp & Dohme
Compounds and compositions as protein kinase inhibitors

TBA
Trisubstituted purine derivatives

Cyclacel
Triazole compounds as KSP inhibitors

Novartis
Inhibitors

Probiodrug
Inhibitors of protein kinases

Portola Pharmaceuticals
Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors

Amgen
Role of the four conserved histidine residues in the amidotransferase domain of carbamoyl phosphate synthetase.

Texas A&M University
Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds.

National Yang-Ming University
Synthesis and Biological Evaluation of N-aryl-4-aryl-1,3-Thiazole-2-Amine Derivatives as Direct 5-Lipoxygenase Inhibitors.

Korea Research Institute of Chemical Technology
Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin.

University of Tokyo
Pharmacological characterization of human S1P4 using a novel radioligand, [4,5-3H]-dihydrosphingosine-1-phosphate.

Schering-Plough Research Institute
Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines.

Harvard University
In vitro characterization of [3H]MethoxyPyEP, an mGluR5 selective radioligand.

Merck Research Laboratories
L-homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists.

Case Western Reserve University
Identification of a novel human eicosanoid receptor coupled to G(i/o).

Tanabe Seiyaku
5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle.

University of Oslo
Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.

Sri International
A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis.

The University of Tokyo
YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.

Yamanouchi Pharmaceutical
Structural combination of established 5-HT(2A) receptor ligands: new aspects of the binding mode.

University of Mainz
A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain.

Eli Lilly
Binding of selective antagonists to four muscarinic receptors (M1 to M4) in rat forebrain.

UniversitÉ
Carbonic anhydrase inhibitors: inhibition of cytosolic carbonic anhydrase isozymes II and VII with simple aromatic sulfonamides and some azo dyes.

Universita Degli Studi Di Firenze
Characteristics of 125I-iodocyanopindolol binding to beta-adrenergic and serotonin-1B receptors of rat brain: selectivity of beta-adrenergic agents.

Niigata College of Pharmacy
SDZ 205-557, a selective, surmountable antagonist for 5-HT4 receptors in the isolated guinea pig ileum.

Sandoz Pharma
Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator.

University of New Mexico
Alpha-noradrenergic receptor binding in mammalian brain: differential labeling of agonist and antagonist states.

TBA
Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.

University of Luxembourg